"Analysis.group","Analysis.number","Analysis.name","Subgroup","Subgroup.number","Applicability","Study","Study.year","GIV.Mean","GIV.SE","Experimental.mean","Experimental.SD","Experimental.cases","Experimental.N","Control.mean","Control.SD","Control.cases","Control.N","O.E","Variance","Weight","Mean","CI.start","CI.end","Footnotes","review.url","review.doi","analysis_key","dataset_name","mismatch_type","direction_match","or_sig","rd_sig","log_or","rd","log_or_ci_lb","log_or_ci_ub","rd_ci_lb","rd_ci_ub","sparse_events","double_zero"
2,2,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Blauenfeldt 2023",2023,0,0.295553767026986,0,0,22,436,0,0,27,393,0,0.0873520292038416,11.787432,0.734455,0.425369,1.268131,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
2,2,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","England 2017",2017,0,0,0,0,0,13,0,0,2,13,0,0,0.477379,0.2,0.010525,3.800646,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
2,2,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","England 2019",2019,0,0.931566472107076,0,0,2,31,0,0,6,29,0,0.867816091954023,1.765292,0.311828,0.068331,1.423024,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
2,2,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Guo 2025",2025,0,0,0,0,35,270,0,0,34,266,0,0,16.718617,1.014161,0.652808,1.575538,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
2,2,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","He 2020",2020,0,0,0,0,1,24,0,0,0,25,0,0,0.416653,3.12,0.133275,73.039718,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
2,2,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Kerstens 2023",2023,0,0,0,0,3,40,0,0,6,48,0,0,2.3145,0.6,0.160144,2.247978,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
2,2,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Li 2018",2018,0,0,0,0,0,29,0,0,2,31,0,0,0.461476,0.213333,0.010672,4.264527,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
2,2,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Li 2020",2020,0,0,0,0,2,24,0,0,4,24,0,0,1.592287,0.5,0.100918,2.477269,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
2,2,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Poalelungi 2021",2021,0,0,0,0,1,18,0,0,0,22,0,0,0.419497,3.631579,0.156808,84.105266,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
2,4,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Blauenfeldt 2023",2023,0,0.295949975887905,0,0,22,377,0,0,27,292,0,0.0875863882280514,13.638841,0.631103,0.367114,1.084924,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
2,4,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Che 2019",2019,0,0,0,0,0,15,0,0,1,15,0,0,0.535433,0.333333,0.01465,7.584305,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
2,4,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","England 2017",2017,0,0,0,0,0,13,0,0,2,13,0,0,0.602207,0.2,0.010525,3.800646,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
2,4,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","England 2019",2019,0,0.931566472107076,0,0,2,31,0,0,6,29,0,0.867816091954023,2.200914,0.311828,0.068331,1.423024,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
2,4,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Guo 2025",2025,0,0,0,0,35,270,0,0,34,266,0,0,18.357753,1.014161,0.652808,1.575538,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
2,4,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Kerstens 2023",2023,0,0,0,0,3,40,0,0,6,48,0,0,2.871367,0.6,0.160144,2.247978,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
2,4,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Li 2024",2024,0,0,0,0,1,37,0,0,5,40,0,0,1.171987,0.216216,0.026478,1.765612,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
2,4,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Poalelungi 2021",2021,0,0,0,0,1,18,0,0,0,22,0,0,0.529471,3.631579,0.156808,84.105266,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
2,4,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)","delayed RIC",2,"SUBGROUP_AND_OVERALL","Chen 2022",2022,0,0,0,0,7,863,0,0,6,913,0,0,4.143402,1.23426,0.416456,3.658004,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.228755519837376,0.0131687262149808,0.0858603128753741,0.371650726799377,-0.0160055209279348,0.0423429733578965,TRUE,TRUE
2,4,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)","delayed RIC",2,"SUBGROUP_AND_OVERALL","He 2020",2020,0,0,0,0,1,24,0,0,0,25,0,0,0.525895,3.12,0.133275,73.039718,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.228755519837376,0.0131687262149808,0.0858603128753741,0.371650726799377,-0.0160055209279348,0.0423429733578965,TRUE,TRUE
2,4,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)","delayed RIC",2,"SUBGROUP_AND_OVERALL","Li 2018",2018,0,0,0,0,0,29,0,0,2,31,0,0,0.582232,0.213333,0.010672,4.264527,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.228755519837376,0.0131687262149808,0.0858603128753741,0.371650726799377,-0.0160055209279348,0.0423429733578965,TRUE,TRUE
2,4,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)","delayed RIC",2,"SUBGROUP_AND_OVERALL","Li 2020",2020,0,0,0,0,2,24,0,0,4,24,0,0,1.988333,0.5,0.100918,2.477269,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.228755519837376,0.0131687262149808,0.0858603128753741,0.371650726799377,-0.0160055209279348,0.0423429733578965,TRUE,TRUE
2,5,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Blauenfeldt 2023",2023,0,0.295949975887905,0,0,22,377,0,0,27,393,0,0.0875863882280514,7.390181,0.849396,0.492561,1.464739,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
2,5,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Che 2019",2019,0,1.67336436944866,0,0,0,15,0,0,1,15,0,2.8001483129403,0.230999,0.333333,0.01465,7.584305,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
2,5,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","England 2017",2017,0,1.60032202878458,0,0,0,13,0,0,2,13,0,2.5610305958132,0.260089,0.2,0.010525,3.800646,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
2,5,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","England 2019",2019,0,0.931566472107076,0,0,2,31,0,0,6,29,0,0.867816091954023,0.975902,0.311828,0.068331,1.423024,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
2,5,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Guo 2025",2025,0,0,0,0,35,270,0,0,34,266,0,0,11.141844,1.014161,0.652808,1.575538,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
2,5,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","He 2020",2020,0,1.65784062696947,0,0,1,24,0,0,0,25,0,2.74843554443054,0.226849,3.12,0.133275,73.039718,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
2,5,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Kerstens 2023",2023,0,0.742183636869307,0,0,3,40,0,0,6,48,0,0.550836550836551,1.287581,0.6,0.160144,2.247978,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
2,5,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Li 2020",2020,0,0.919486022435657,0,0,2,24,0,0,4,24,0,0.845454545454545,0.878528,0.5,0.100918,2.477269,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
2,5,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Poalelungi 2021",2021,0,1.66380707062266,0,0,1,18,0,0,0,22,0,2.76825396825397,0.228405,3.631579,0.156808,84.105266,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
2,5,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Zhang 2022",2022,0,1.66266663701889,0,0,0,19,0,0,1,22,0,2.76446034585569,0.228172,0.383333,0.016525,8.892066,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
2,5,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)","medium-duration RIC",2,"SUBGROUP_AND_OVERALL","Chen 2022",2022,0,0.558385681814362,0,0,7,863,0,0,6,913,0,0.311794569655289,1.898719,1.23426,0.416456,3.658004,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.260644234951404,0.041899961640965,0.121624191057738,0.39966427884507,-0.0301322911269109,0.113932214408841,TRUE,TRUE
2,5,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)","medium-duration RIC",2,"SUBGROUP_AND_OVERALL","Li 2018",2018,0,1.5709222164606,0,0,0,29,0,0,2,31,0,2.46779661016949,0.25138,0.213333,0.010672,4.264527,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.260644234951404,0.041899961640965,0.121624191057738,0.39966427884507,-0.0301322911269109,0.113932214408841,TRUE,TRUE
2,5,"Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)","medium-duration RIC",2,"SUBGROUP_AND_OVERALL","Li 2024",2024,0,1.12086984362557,0,0,1,37,0,0,5,40,0,1.25634920634921,0.510902,0.216216,0.026478,1.765612,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.260644234951404,0.041899961640965,0.121624191057738,0.39966427884507,-0.0301322911269109,0.113932214408841,TRUE,TRUE
3,2,"Subgroup analysis, excellent functional outcomes (mRS 0-1) at 90 days (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","England 2019",2019,0,0.55048188256318,0,0,9,31,0,0,11,29,0,0.303030303030303,2.449169,0.765396,0.37223,1.573842,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
3,2,"Subgroup analysis, excellent functional outcomes (mRS 0-1) at 90 days (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Guo 2025",2025,0,0.0714130628637838,0,0,168,268,0,0,150,264,0,0.0050998255475867,20.79316,1.103284,0.95918,1.269036,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
3,2,"Subgroup analysis, excellent functional outcomes (mRS 0-1) at 90 days (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","He 2020",2020,0,0.601332942045871,0,0,15,24,0,0,17,25,0,0.361601307189542,6.441561,0.919118,0.60979,1.385359,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
3,2,"Subgroup analysis, excellent functional outcomes (mRS 0-1) at 90 days (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Landman 2023",2023,0,0.491080153819625,0,0,20,31,0,0,19,40,0,0.241159717475507,6.268385,1.358234,0.894664,2.062005,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
3,2,"Subgroup analysis, excellent functional outcomes (mRS 0-1) at 90 days (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Li 2018",2018,0,0.653278827739907,0,0,7,29,0,0,5,31,0,0.426773226773227,1.253133,1.496552,0.534334,4.191511,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
3,2,"Subgroup analysis, excellent functional outcomes (mRS 0-1) at 90 days (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Pico 2020",2020,0,0.297883885934482,0,0,46,90,0,0,37,95,0,0.0887348094994271,9.17035,1.312312,0.950249,1.812329,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
3,4,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","An 2020",2020,0,0.521762810867357,0,0,23,32,0,0,17,34,0,0.272236430804206,6.702409,1.4375,0.963635,2.144387,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
3,4,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","England 2019",2019,0,0.55048188256318,0,0,9,31,0,0,11,29,0,0.303030303030303,2.449169,0.765396,0.37223,1.573842,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
3,4,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Guo 2025",2025,0,0.0714130628637838,0,0,168,268,0,0,150,264,0,0.0050998255475867,20.79316,1.103284,0.95918,1.269036,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
3,4,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","He 2020",2020,0,0.601332942045871,0,0,15,24,0,0,17,25,0,0.361601307189542,6.441561,0.919118,0.60979,1.385359,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
3,4,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Hougaard 2014",2014,0,0.304294608636448,0,0,96,133,0,0,66,91,0,0.0925952088452088,18.685439,0.995215,0.8441,1.173384,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
3,4,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Landman 2023",2023,0,0.491080153819625,0,0,20,31,0,0,19,40,0,0.241159717475507,6.268385,1.358234,0.894664,2.062005,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
3,4,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Pico 2020",2020,0,0.297883885934482,0,0,46,90,0,0,37,95,0,0.0887348094994271,9.17035,1.312312,0.950249,1.812329,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
3,4,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)","delayed RIC",2,"SUBGROUP_AND_OVERALL","Chen 2022",2022,0,0.0996271085213732,0,0,582,863,0,0,566,913,0,0.0099255607523294,26.746894,1.087844,1.015552,1.165282,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.228755519837376,0.0131687262149808,0.0858603128753741,0.371650726799377,-0.0160055209279348,0.0423429733578965,TRUE,TRUE
3,4,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)","delayed RIC",2,"SUBGROUP_AND_OVERALL","Li 2018",2018,0,0.653278827739907,0,0,7,29,0,0,5,31,0,0.426773226773227,1.253133,1.496552,0.534334,4.191511,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.228755519837376,0.0131687262149808,0.0858603128753741,0.371650726799377,-0.0160055209279348,0.0423429733578965,TRUE,TRUE
3,5,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","England 2019",2019,0,0.55048188256318,0,0,9,31,0,0,11,29,0,0.303030303030303,2.449169,0.765396,0.37223,1.573842,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
3,5,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Guo 2025",2025,0,0.0714130628637838,0,0,168,268,0,0,150,264,0,0.0050998255475867,20.79316,1.103284,0.95918,1.269036,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
3,5,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","He 2020",2020,0,0.601332942045871,0,0,15,24,0,0,17,25,0,0.361601307189542,6.441561,0.919118,0.60979,1.385359,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
3,5,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Hougaard 2014",2014,0,0.304294608636448,0,0,96,133,0,0,66,91,0,0.0925952088452088,18.685439,0.995215,0.8441,1.173384,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
3,5,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Landman 2023",2023,0,0.491080153819625,0,0,20,31,0,0,19,40,0,0.241159717475507,6.268385,1.358234,0.894664,2.062005,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
3,5,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Pico 2020",2020,0,0.297883885934482,0,0,46,90,0,0,37,95,0,0.0887348094994271,9.17035,1.312312,0.950249,1.812329,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
3,5,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)","medium-duration RIC",2,"SUBGROUP_AND_OVERALL","An 2020",2020,0,0.521762810867357,0,0,23,32,0,0,17,34,0,0.272236430804206,6.702409,1.4375,0.963635,2.144387,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.260644234951404,0.041899961640965,0.121624191057738,0.39966427884507,-0.0301322911269109,0.113932214408841,TRUE,TRUE
3,5,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)","medium-duration RIC",2,"SUBGROUP_AND_OVERALL","Chen 2022",2022,0,0.0996271085213732,0,0,582,863,0,0,566,913,0,0.0099255607523294,26.746894,1.087844,1.015552,1.165282,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.260644234951404,0.041899961640965,0.121624191057738,0.39966427884507,-0.0301322911269109,0.113932214408841,TRUE,TRUE
3,5,"Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)","medium-duration RIC",2,"SUBGROUP_AND_OVERALL","Li 2018",2018,0,0.653278827739907,0,0,7,29,0,0,5,31,0,0.426773226773227,1.253133,1.496552,0.534334,4.191511,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.260644234951404,0.041899961640965,0.121624191057738,0.39966427884507,-0.0301322911269109,0.113932214408841,TRUE,TRUE
5,2,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Blauenfeldt 2023",2023,0,0.14211724326481,0,0,297,436,0,0,310,466,0,0.0201973108331892,18.318733,1.023986,0.934965,1.121484,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
5,2,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","England 2019",2019,0,0.5235075456724,0,0,19,31,0,0,15,29,0,0.27406015037594,1.746085,1.184946,0.756062,1.85712,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
5,2,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Guo 2025",2025,0,0.0445198740264938,0,0,211,268,0,0,210,264,0,0.0019820191833348,18.929291,0.989765,0.907062,1.08001,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
5,2,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","He 2020",2020,0,0.686971487444278,0,0,19,24,0,0,19,25,0,0.471929824561403,3.636223,1.041667,0.770858,1.407612,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
5,2,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Landman 2023",2023,0,0.563788207447746,0,0,24,31,0,0,30,40,0,0.317857142857143,4.65485,1.032258,0.795077,1.340193,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
5,2,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Pico 2020",2020,0,0.317439835488783,0,0,62,90,0,0,60,91,0,0.100768049155146,7.022581,1.044815,0.853117,1.279588,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
5,2,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Zhang 2022",2022,0,0.643602877731808,0,0,12,19,0,0,13,22,0,0.414224664224664,1.489151,1.068826,0.655645,1.74239,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
5,4,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","An 2020",2020,0,0.571451464742874,0,0,26,32,0,0,20,34,0,0.326556776556777,3.142504,1.38125,0.996206,1.915117,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
5,4,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Blauenfeldt 2023",2023,0,0.14211724326481,0,0,297,436,0,0,310,466,0,0.0201973108331892,18.318733,1.023986,0.934965,1.121484,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
5,4,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","England 2019",2019,0,0.5235075456724,0,0,19,31,0,0,15,29,0,0.27406015037594,1.746085,1.184946,0.756062,1.85712,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
5,4,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Guo 2025",2025,0,0.0445198740264938,0,0,211,268,0,0,210,264,0,0.0019820191833348,18.929291,0.989765,0.907062,1.08001,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
5,4,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","He 2020",2020,0,0.686971487444278,0,0,19,24,0,0,19,25,0,0.471929824561403,3.636223,1.041667,0.770858,1.407612,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
5,4,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Hougaard 2014",2014,0,0.388865560011622,0,0,107,133,0,0,80,91,0,0.151216423763153,14.977543,0.915132,0.817156,1.024854,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
5,4,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Landman 2023",2023,0,0.563788207447746,0,0,24,31,0,0,30,40,0,0.317857142857143,4.65485,1.032258,0.795077,1.340193,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
5,4,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Li 2024",2024,0,0.552179283190083,0,0,17,37,0,0,6,40,0,0.304901960784314,0.5508,3.063063,1.354066,6.929025,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
5,4,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Pico 2020",2020,0,0.317439835488783,0,0,62,90,0,0,60,91,0,0.100768049155146,7.022581,1.044815,0.853117,1.279588,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
5,4,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)","delayed RIC",2,"SUBGROUP_AND_OVERALL","Chen 2022",2022,0,0.114250106265442,0,0,687,863,0,0,689,913,0,0.0130530867816646,25.53224,1.054866,1.003337,1.109042,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.228755519837376,0.0131687262149808,0.0858603128753741,0.371650726799377,-0.0160055209279348,0.0423429733578965,TRUE,TRUE
5,4,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)","delayed RIC",2,"SUBGROUP_AND_OVERALL","Zhang 2022",2022,0,0.643602877731808,0,0,12,19,0,0,13,22,0,0.414224664224664,1.489151,1.068826,0.655645,1.74239,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.228755519837376,0.0131687262149808,0.0858603128753741,0.371650726799377,-0.0160055209279348,0.0423429733578965,TRUE,TRUE
5,5,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Blauenfeldt 2023",2023,0,0.14211724326481,0,0,297,436,0,0,310,466,0,0.0201973108331892,18.318733,1.023986,0.934965,1.121484,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
5,5,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","England 2019",2019,0,0.5235075456724,0,0,19,31,0,0,15,29,0,0.27406015037594,1.746085,1.184946,0.756062,1.85712,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
5,5,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Guo 2025",2025,0,0.0445198740264938,0,0,211,268,0,0,210,264,0,0.0019820191833348,18.929291,0.989765,0.907062,1.08001,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
5,5,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","He 2020",2020,0,0.686971487444278,0,0,19,24,0,0,19,25,0,0.471929824561403,3.636223,1.041667,0.770858,1.407612,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
5,5,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Hougaard 2014",2014,0,0.388865560011622,0,0,107,133,0,0,80,91,0,0.151216423763153,14.977543,0.915132,0.817156,1.024854,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
5,5,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Landman 2023",2023,0,0.563788207447746,0,0,24,31,0,0,30,40,0,0.317857142857143,4.65485,1.032258,0.795077,1.340193,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
5,5,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Pico 2020",2020,0,0.317439835488783,0,0,62,90,0,0,60,91,0,0.100768049155146,7.022581,1.044815,0.853117,1.279588,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
5,5,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Zhang 2022",2022,0,0.643602877731808,0,0,12,19,0,0,13,22,0,0.414224664224664,1.489151,1.068826,0.655645,1.74239,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
5,5,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)","medium-duration RIC",2,"SUBGROUP_AND_OVERALL","An 2020",2020,0,0.571451464742874,0,0,26,32,0,0,20,34,0,0.326556776556777,3.142504,1.38125,0.996206,1.915117,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.260644234951404,0.041899961640965,0.121624191057738,0.39966427884507,-0.0301322911269109,0.113932214408841,TRUE,TRUE
5,5,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)","medium-duration RIC",2,"SUBGROUP_AND_OVERALL","Chen 2022",2022,0,0.114250106265442,0,0,687,863,0,0,689,913,0,0.0130530867816646,25.53224,1.054866,1.003337,1.109042,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.260644234951404,0.041899961640965,0.121624191057738,0.39966427884507,-0.0301322911269109,0.113932214408841,TRUE,TRUE
5,5,"Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)","medium-duration RIC",2,"SUBGROUP_AND_OVERALL","Li 2024",2024,0,0.552179283190083,0,0,17,37,0,0,6,40,0,0.304901960784314,0.5508,3.063063,1.354066,6.929025,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.260644234951404,0.041899961640965,0.121624191057738,0.39966427884507,-0.0301322911269109,0.113932214408841,TRUE,TRUE
7,2,"Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","England 2017",2017,0,1.83844625033875,-3.3,4.21,0,13,1.1,5.12,0,13,0,3.37988461538462,3.290756,-4.4,-8.003288,-0.796712,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
7,2,"Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","England 2019",2019,0,1.46119243542161,-3,3.8,0,30,-1.4,6.3,0,24,0,2.13508333333333,4.503449,-1.6,-4.463885,1.263885,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
7,2,"Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Guo 2025",2025,0,0.317272382513641,-4,3.7,0,272,-4,3.7,0,272,0,0.100661764705882,11.323076,0,-0.621842,0.621842,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
7,2,"Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","He 2020",2020,0,0.540610919855183,1.5,0.79,0,24,2,2.58,0,25,0,0.292260166666667,9.909788,-0.5,-1.559578,0.559578,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
7,2,"Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","He 2022",2022,0,0.297742831401184,-5.54,1.61,0,63,-3.2,1.73,0,63,0,0.0886507936507936,11.425221,-2.34,-2.923565,-1.756435,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
7,2,"Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Landman 2023",2023,0,1.0388771772802,-0.25,4.89,0,38,-1.25,4.5,0,45,0,1.07926578947368,6.551117,1,-1.036162,3.036162,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
7,2,"Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Li 2018",2018,0,0.802195263872401,-3.39,2.79,0,29,-2.11,3.41,0,31,0,0.64351724137931,8.064456,-1.28,-2.852274,0.292274,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
7,2,"Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Li 2020",2020,0,0.707348334745101,-6,2.41,0,24,-5.83,2.49,0,24,0,0.500341666666667,8.726842,-0.17,-1.556377,1.216377,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
7,2,"Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Pico 2020",2020,0,0.113781132048274,-0.59,0.78,0,93,-0.51,0.78,0,95,0,0.0129461460101867,12.114008,-0.08,-0.303007,0.143007,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
7,4,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Che 2019",2019,0,0.473427220735493,-0.33,0.82,0,15,-1,1.64,0,15,0,0.224133333333333,10.370015,0.67,-0.2579,1.5979,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
7,4,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","England 2017",2017,0,1.83844625033875,-3.3,4.21,0,13,1.1,5.12,0,13,0,3.37988461538462,3.290756,-4.4,-8.003288,-0.796712,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
7,4,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","England 2019",2019,0,1.46119243542161,-3,3.8,0,30,-1.4,6.3,0,24,0,2.13508333333333,4.503449,-1.6,-4.463885,1.263885,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
7,4,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Guo 2025",2025,0,0.317272382513641,-4,3.7,0,272,-4,3.7,0,272,0,0.100661764705882,11.323076,0,-0.621842,0.621842,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
7,4,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","He 2020",2020,0,0.540610919855183,1.5,0.79,0,24,2,2.58,0,25,0,0.292260166666667,9.909788,-0.5,-1.559578,0.559578,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
7,4,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","He 2022",2022,0,0.297742831401184,-5.54,1.61,0,63,-3.2,1.73,0,63,0,0.0886507936507936,11.425221,-2.34,-2.923565,-1.756435,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
7,4,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Landman 2023",2023,0,1.0388771772802,-0.25,4.89,0,38,-1.25,4.5,0,45,0,1.07926578947368,6.551117,1,-1.036162,3.036162,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
7,4,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Li 2024",2024,0,1.46221265915647,-6,5.19,0,37,-0.25,7.32,0,38,0,2.13806586059744,4.499476,-5.75,-8.615884,-2.884116,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
7,4,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Pico 2020",2020,0,0.113781132048274,-0.59,0.78,0,93,-0.51,0.78,0,95,0,0.0129461460101867,12.114008,-0.08,-0.303007,0.143007,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
7,4,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)","delayed RIC",2,"SUBGROUP_AND_OVERALL","Li 2018",2018,0,0.802195263872401,-3.39,2.79,0,29,-2.11,3.41,0,31,0,0.64351724137931,8.064456,-1.28,-2.852274,0.292274,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.228755519837376,0.0131687262149808,0.0858603128753741,0.371650726799377,-0.0160055209279348,0.0423429733578965,TRUE,TRUE
7,4,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)","delayed RIC",2,"SUBGROUP_AND_OVERALL","Li 2020",2020,0,0.707348334745101,-6,2.41,0,24,-5.83,2.49,0,24,0,0.500341666666667,8.726842,-0.17,-1.556377,1.216377,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.228755519837376,0.0131687262149808,0.0858603128753741,0.371650726799377,-0.0160055209279348,0.0423429733578965,TRUE,TRUE
7,5,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Che 2019",2019,0,0.473427220735493,-0.33,0.82,0,15,-1,1.64,0,15,0,0.224133333333333,10.370015,0.67,-0.2579,1.5979,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
7,5,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","England 2017",2017,0,1.83844625033875,-3.3,4.21,0,13,1.1,5.12,0,13,0,3.37988461538462,3.290756,-4.4,-8.003288,-0.796712,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
7,5,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","England 2019",2019,0,1.46119243542161,-3,3.8,0,30,-1.4,6.3,0,24,0,2.13508333333333,4.503449,-1.6,-4.463885,1.263885,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
7,5,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Guo 2025",2025,0,0.317272382513641,-4,3.7,0,272,-4,3.7,0,272,0,0.100661764705882,11.323076,0,-0.621842,0.621842,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
7,5,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","He 2020",2020,0,0.540610919855183,1.5,0.79,0,24,2,2.58,0,25,0,0.292260166666667,9.909788,-0.5,-1.559578,0.559578,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
7,5,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","He 2022",2022,0,0.297742831401184,-5.54,1.61,0,63,-3.2,1.73,0,63,0,0.0886507936507936,11.425221,-2.34,-2.923565,-1.756435,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
7,5,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Landman 2023",2023,0,1.0388771772802,-0.25,4.89,0,38,-1.25,4.5,0,45,0,1.07926578947368,6.551117,1,-1.036162,3.036162,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
7,5,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Li 2020",2020,0,0.707348334745101,-6,2.41,0,24,-5.83,2.49,0,24,0,0.500341666666667,8.726842,-0.17,-1.556377,1.216377,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
7,5,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)","short-duration RIC",1,"SUBGROUP_AND_OVERALL","Pico 2020",2020,0,0.113781132048274,-0.59,0.78,0,93,-0.51,0.78,0,95,0,0.0129461460101867,12.114008,-0.08,-0.303007,0.143007,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
7,5,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)","medium-duration RIC",2,"SUBGROUP_AND_OVERALL","Li 2018",2018,0,0.802195263872401,-3.39,2.79,0,29,-2.11,3.41,0,31,0,0.64351724137931,8.064456,-1.28,-2.852274,0.292274,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.260644234951404,0.041899961640965,0.121624191057738,0.39966427884507,-0.0301322911269109,0.113932214408841,TRUE,TRUE
7,5,"Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)","medium-duration RIC",2,"SUBGROUP_AND_OVERALL","Li 2024",2024,0,1.46221265915647,-6,5.19,0,37,-0.25,7.32,0,38,0,2.13806586059744,4.499476,-5.75,-8.615884,-2.884116,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.260644234951404,0.041899961640965,0.121624191057738,0.39966427884507,-0.0301322911269109,0.113932214408841,TRUE,TRUE
8,2,"Cardiovascular events during follow-up (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Blauenfeldt 2023",2023,0,0,0,0,57,435,0,0,62,466,0,0,49.351287,0.984872,0.70446,1.376903,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
8,2,"Cardiovascular events during follow-up (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","England 2017",2017,0,0,0,0,0,13,0,0,1,13,0,0,0.571535,0.333333,0.014812,7.501364,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
8,2,"Cardiovascular events during follow-up (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","England 2019",2019,0,0,0,0,0,30,0,0,0,24,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
8,2,"Cardiovascular events during follow-up (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Li 2020",2020,0,0,0,0,0,24,0,0,1,24,0,0,0.557646,0.333333,0.014252,7.796078,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
8,2,"Cardiovascular events during follow-up (based on unilateral or bilateral limb RIC intervention)","unilateral limb",1,"SUBGROUP_AND_OVERALL","Pico 2020",2020,0,0,0,0,0,94,0,0,1,94,0,0,0.545221,0.333333,0.013752,8.079552,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","2::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0595779007413067,-0.00697665309962445,-0.0756661302133858,0.194821931695999,-0.0202111827528762,0.00625787655362732,TRUE,TRUE
8,4,"Cardiovascular events during follow-up (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Blauenfeldt 2023",2023,0,0,0,0,57,435,0,0,62,466,0,0,49.351287,0.984872,0.70446,1.376903,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
8,4,"Cardiovascular events during follow-up (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Che 2019",2019,0,0,0,0,0,15,0,0,1,15,0,0,0.567519,0.333333,0.01465,7.584305,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
8,4,"Cardiovascular events during follow-up (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","England 2017",2017,0,0,0,0,0,13,0,0,1,13,0,0,0.571535,0.333333,0.014812,7.501364,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
8,4,"Cardiovascular events during follow-up (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","England 2019",2019,0,0,0,0,0,30,0,0,0,24,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
8,4,"Cardiovascular events during follow-up (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Li 2024",2024,0,0,0,0,10,37,0,0,16,40,0,0,13.056997,0.675676,0.352225,1.296153,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
8,4,"Cardiovascular events during follow-up (based on RIC intervention timing)","acute RIC",1,"SUBGROUP_AND_OVERALL","Pico 2020",2020,0,0,0,0,0,94,0,0,1,94,0,0,0.545221,0.333333,0.013752,8.079552,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0598548390362853,-0.00827186929862411,-0.0677701041219677,0.187479782194538,-0.0221497473108296,0.00560600871358134,TRUE,TRUE
8,4,"Cardiovascular events during follow-up (based on RIC intervention timing)","delayed RIC",2,"SUBGROUP_AND_OVERALL","Li 2020",2020,0,0,0,0,0,24,0,0,1,24,0,0,0.557646,0.333333,0.014252,7.796078,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","4::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.228755519837376,0.0131687262149808,0.0858603128753741,0.371650726799377,-0.0160055209279348,0.0423429733578965,TRUE,TRUE
8,5,"Cardiovascular events during follow-up( based on the duration of RIC intervention)","short-duration",1,"SUBGROUP_AND_OVERALL","Blauenfeldt 2023",2023,0,0,0,0,57,435,0,0,62,466,0,0,49.351287,0.984872,0.70446,1.376903,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
8,5,"Cardiovascular events during follow-up( based on the duration of RIC intervention)","short-duration",1,"SUBGROUP_AND_OVERALL","Che 2019",2019,0,0,0,0,0,15,0,0,1,15,0,0,0.567519,0.333333,0.01465,7.584305,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
8,5,"Cardiovascular events during follow-up( based on the duration of RIC intervention)","short-duration",1,"SUBGROUP_AND_OVERALL","England 2017",2017,0,0,0,0,0,13,0,0,1,13,0,0,0.571535,0.333333,0.014812,7.501364,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
8,5,"Cardiovascular events during follow-up( based on the duration of RIC intervention)","short-duration",1,"SUBGROUP_AND_OVERALL","England 2019",2019,0,0,0,0,0,30,0,0,0,24,0,0,NA,NA,NA,NA,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
8,5,"Cardiovascular events during follow-up( based on the duration of RIC intervention)","short-duration",1,"SUBGROUP_AND_OVERALL","Li 2020",2020,0,0,0,0,0,24,0,0,1,24,0,0,0.557646,0.333333,0.014252,7.796078,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
8,5,"Cardiovascular events during follow-up( based on the duration of RIC intervention)","short-duration",1,"SUBGROUP_AND_OVERALL","Pico 2020",2020,0,0,0,0,0,94,0,0,1,94,0,0,0.545221,0.333333,0.013752,8.079552,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::1","CD012503_pub3_data","direction_only",FALSE,FALSE,FALSE,0.0380360869996252,-0.00805366805420445,-0.0924241837440559,0.168496357743306,-0.0210959127127803,0.00498857660437138,TRUE,TRUE
8,5,"Cardiovascular events during follow-up( based on the duration of RIC intervention)","medium-duration",2,"SUBGROUP_AND_OVERALL","Li 2024",2024,0,0,0,0,10,37,0,0,16,40,0,0,13.056997,0.675676,0.352225,1.296153,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012503.pub3/full","10.1002/14651858.CD012503.pub3","5::2","CD012503_pub3_data","significance_only",TRUE,TRUE,FALSE,0.260644234951404,0.041899961640965,0.121624191057738,0.39966427884507,-0.0301322911269109,0.113932214408841,TRUE,TRUE
